Integra LifeSciences
IART
280 hedge funds and large institutions have $4.13B invested in Integra LifeSciences in 2022 Q4 according to their latest regulatory filings, with 42 funds opening new positions, 93 increasing their positions, 97 reducing their positions, and 38 closing their positions.
50% more funds holding in top 10
Funds holding in top 10: 2 → 3 (+1)
32% more capital invested
Capital invested by funds: $3.13B → $4.13B (+$1B)
11% more first-time investments, than exits
New positions opened: 42 | Existing positions closed: 38
0.02% less ownership
Funds ownership: 88.37% → 88.35% (-0.02%)
1% less funds holding
Funds holding: 282 → 280 (-2)
4% less repeat investments, than reductions
Existing positions increased: 93 | Existing positions reduced: 97
24% less call options, than puts
Call options by funds: $12.5M | Put options by funds: $16.4M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
+$273M |
| 2 |
Select Equity Group
New York
|
+$42.8M |
| 3 |
Fuller & Thaler Asset Management
San Mateo,
California
|
+$36.3M |
| 4 |
Capital Research Global Investors
Los Angeles,
California
|
+$35.8M |
| 5 |
AllianceBernstein
Nashville,
Tennessee
|
+$19.6M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Janus Henderson Group
London,
|
-$27.2M |
| 2 |
Franklin Resources
San Mateo,
California
|
-$11.8M |
| 3 |
Two Sigma Investments
New York
|
-$11.3M |
| 4 |
Renaissance Technologies
New York
|
-$10.6M |
| 5 |
Balyasny Asset Management
Chicago,
Illinois
|
-$9.14M |
IART Hedge Fund Activity: Q4 2022 in Review
280 of the 6,237 institutional investors tracked by Wall St. Rank reported a position in Integra LifeSciences (IART) for Q4 2022, worth a combined $4.13B — up 32% from $3.13B a quarter earlier.
Buyers outnumbered sellers: 42 funds opened new IART positions and 38 closed out — a net gain of 4 holders — while 93 added to existing stakes and 97 trimmed.
The largest buyer was Morgan Stanley, adding an estimated $273M. The largest seller was Janus Henderson Group, cutting an estimated $27.2M.
- 280 institutional investors held Integra LifeSciences (IART) as of Q4 2022, down from 282 in Q3 2022.
- Funds reported $4.13B of Integra LifeSciences stock for Q4 2022, up 32% quarter-over-quarter.
- 42 funds opened new Integra LifeSciences positions in Q4 2022 and 38 closed out, a net change of +4 holders.
- The largest Integra LifeSciences buyer in Q4 2022 was Morgan Stanley, an estimated $273M added.
- The largest Integra LifeSciences seller in Q4 2022 was Janus Henderson Group, an estimated $27.2M sold.
Based on aggregated 13F filings for Q4 2022.